Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | LMB-100 |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung adenocarcinoma | no benefit | LMB-100 | Preclinical - Cell culture | Actionable | In a preclinical study, a CD274 (PD-L1) positive mouse lung adenocarcinoma cell line was not sensitive to treatment with LMB-100 in culture (PMID: 32611684). | 32611684 |
PubMed Id | Reference Title | Details |
---|---|---|
(32611684) | Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. | Full reference... |